US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Virtus U.S. Dividend ETF

29.70

-0.0631-0.21%

Post-market: 29.770.0631+0.21%16:54 EDT

Volume:36

Turnover:1K

Market Cap:17.82M

PE:- -

High:29.70

Open:29.77

Low:29.70

Close:29.77

52wk High:30.24

52wk Low:24.79

Shares:600.00K

Float Shares:600.00K

Volume Ratio:0.94

T/O Rate:0.01%

Dividend:0.38

Dividend Rate:1.30%

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

Rhythm Pharmaceuticals to Report Second Quarter 2026 Financial Results on Tuesday, August 4, 2026

Rhythm Pharmaceuticals Announces The New England Journal of Medicine Publication of Phase 3 TRANSCEND Trial Results in Acquired Hypothalamic Obesity

Rhythm Pharmaceuticals Announces Multiple New Data Presentations from MC4R Agonists in Acquired Hypothalamic Obesity (HO), Bardet-Biedl Syndrome (BBS) and Prader-Willi Syndrome (PWS) at ENDO 2026

Rhythm Pharmaceuticals to Announce Interim Six-Month Phase 2 Results Evaluating Setmelanotide in Patients with Prader-Willi Syndrome

Lantheus' LNTH-2513 (18F-GP1) PET/CT Awarded SNMMI’s Image of the Year

Rhythm Pharmaceuticals Announces Seven Abstracts Accepted for Presentation at ENDO 2026

Rhythm Pharmaceuticals Announces Publication of New Bardet-Biedl Syndrome Diagnostic Algorithm in the American Journal of Medical Genetics

Rhythm Pharmaceuticals Announces Participation in Upcoming Investor Conferences

Rhythm Pharmaceuticals Announces New Data Presentations at the 2026 European Congress of Endocrinology

Rhythm Pharmaceuticals Announces Participation in Upcoming Bank of America Global Healthcare Conference

Rhythm Pharmaceuticals Reports First Quarter 2026 Financial Results and Business Update

Rhythm Pharmaceuticals Announces New Data Presentations in Acquired Hypothalamic Obesity at Pediatric Endocrine Society

Rhythm Pharmaceuticals Announces IMCIVREE® (Setmelanotide) Granted Marketing Authorization by European Commission for the Treatment of Obesity and Control of Hunger in Patients with Acquired Hypothalamic Obesity

Rhythm Pharmaceuticals to Report First Quarter 2026 Financial Results on Tuesday, May 5, 2026

Rhythm Pharmaceuticals Announces Changes to Board of Directors

Rhythm Pharmaceuticals Receives Positive CHMP Opinion for IMCIVREE® (setmelanotide) for the Treatment of Obesity and Control of Hunger in Patients with Acquired Hypothalamic Obesity due to Hypothalamic Injury or Impairment

Rhythm Pharmaceuticals Announces FDA Approval of IMCIVREE® (setmelanotide) for Patients with Acquired Hypothalamic Obesity

Rhythm Pharmaceuticals Announces Additional Positive Data from Phase 3 TRANSCEND trial of Setmelanotide in Patients with Acquired Hypothalamic Obesity

Rhythm Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results on Thursday, February 26, 2026

Rhythm Pharmaceuticals Announces Participation in Upcoming Guggenheim Biotech Summit

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/VUS/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"VUS","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"VUS\",,,,,undefined,":{"symbol":"VUS","market":"US","secType":"STK","nameCN":"Virtus U.S. Dividend ETF","latestPrice":29.7039,"timestamp":1784923200000,"preClose":29.767,"halted":0,"volume":36,"hourTrading":{"tag":"盘后","latestPrice":29.767,"preClose":29.7039,"latestTime":"16:54 EDT","volume":9,"amount":270.2656,"timestamp":1784926451793,"change":0.0631,"changeRate":0.002124,"amplitude":0},"delay":0,"changeRate":-0.0021197970907380187,"floatShares":600004,"shares":600004,"eps":0,"marketStatus":"Market Closed","change":-0.0631,"latestTime":"07-24 16:00:00 EDT","open":29.767,"high":29.7039,"low":29.7039,"amount":1089,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1785139200000},"marketStatusCode":7,"adr":0,"exchange":"ARCA","adjPreClose":29.767,"sharesOutstanding":625004,"nav":29.723,"aum":17834052.14,"dividendRate":0.012958,"bidAskSpread":0,"postHourTrading":{"tag":"盘后","latestPrice":29.767,"preClose":29.7039,"latestTime":"16:54 EDT","volume":9,"amount":270.2656,"timestamp":1784926451793,"change":0.0631,"changeRate":0.002124,"amplitude":0},"volumeRatio":0.9403658940758095},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"VUS\",,,,,undefined,":{"symbol":"VUS","floatShares":600004,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.9403658940758095,"shares":600004,"dividePrice":0.3849,"high":29.7039,"amplitude":0,"preClose":29.767,"low":29.7039,"week52Low":24.79,"pbRate":"--","week52High":30.2403,"institutionHeld":0,"latestPrice":29.7039,"eps":0,"divideRate":0.012958,"volume":36,"delay":0,"ttmEps":0,"open":29.767,"prevYearClose":25.2797,"prevWeekClose":29.9819,"prevMonthClose":29.8174,"prevQuarterClose":29.8174,"fiveDayClose":29.9819,"twentyDayClose":29.4397,"sixtyDayClose":28.319},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/VUS\",params:#limit:5,,,undefined,":[{"date":"2026-06-22","symbol":"VUS","amount":0.164,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-06-22","defaultRemindTime":1782135000000,"name":"Virtus U.S. Dividend ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-06-29","payableDate":"2026-06-22","currency":"USD","dateTimestamp":1782100800000,"payDate":"2026-06-29"},{"date":"2026-03-20","symbol":"VUS","amount":0.2199,"announcedDate":"2026-03-19","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-03-20","defaultRemindTime":1774013400000,"name":"Virtus U.S. Dividend ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-03-27","payableDate":"2026-03-20","currency":"USD","dateTimestamp":1773979200000,"payDate":"2026-03-27"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"VUS\",market:\"US\",,,undefined,":[{"executeDate":"2026-03-20","recordDate":"2026-03-20","paymentDate":"2026-03-27","value":0.2199,"currency":"USD"},{"executeDate":"2026-06-22","recordDate":"2026-06-22","paymentDate":"2026-06-29","value":0.164,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"VUS\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"VUS\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2653927705","title":"Rhythm Pharmaceuticals to Report Second Quarter 2026 Financial Results on Tuesday, August 4, 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2653927705","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653927705?lang=en_us&edition=fundamental","pubTime":"2026-07-21 20:00","pubTimestamp":1784635200,"startTime":"0","endTime":"0","summary":"BOSTON, July  21, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with ra","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/07/21/3330408/0/en/Rhythm-Pharmaceuticals-to-Report-Second-Quarter-2026-Financial-Results-on-Tuesday-August-4-2026.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EC","VUS","AVP","BK4201"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650919584","title":"Rhythm Pharmaceuticals Announces The New England Journal of Medicine Publication of Phase 3 TRANSCEND Trial Results in Acquired Hypothalamic Obesity","url":"https://stock-news.laohu8.com/highlight/detail?id=2650919584","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2650919584?lang=en_us&edition=fundamental","pubTime":"2026-07-09 05:07","pubTimestamp":1783544820,"startTime":"0","endTime":"0","summary":"BOSTON, July  08, 2026  (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with r","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/07/08/3324480/0/en/Rhythm-Pharmaceuticals-Announces-The-New-England-Journal-of-Medicine-Publication-of-Phase-3-TRANSCEND-Trial-Results-in-Acquired-Hypothalamic-Obesity.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VUS","BK4201","BK4087","CHMP","AVP","BK4157","BMI","EC","BK4081","EMA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643785500","title":"Rhythm Pharmaceuticals Announces Multiple New Data Presentations from MC4R Agonists in Acquired Hypothalamic Obesity (HO), Bardet-Biedl Syndrome (BBS) and Prader-Willi Syndrome (PWS) at ENDO 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2643785500","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643785500?lang=en_us&edition=fundamental","pubTime":"2026-06-16 04:01","pubTimestamp":1781553660,"startTime":"0","endTime":"0","summary":"-- Setmelanotide therapy achieved robust, sustained and clinically significant weight loss in patients with acquired HO at 2.5 years --  -- Bivamelagon therapy achieved progressive reductions in BMI a","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/06/15/3312120/0/en/Rhythm-Pharmaceuticals-Announces-Multiple-New-Data-Presentations-from-MC4R-Agonists-in-Acquired-Hypothalamic-Obesity-HO-Bardet-Biedl-Syndrome-BBS-and-Prader-Willi-Syndrome-PWS-at-E.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VUS","EC","ENDO","PWS","BK4201","AVP","BK4183"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643185082","title":"Rhythm Pharmaceuticals to Announce Interim Six-Month Phase 2 Results Evaluating Setmelanotide in Patients with Prader-Willi Syndrome","url":"https://stock-news.laohu8.com/highlight/detail?id=2643185082","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643185082?lang=en_us&edition=fundamental","pubTime":"2026-06-13 04:01","pubTimestamp":1781294460,"startTime":"0","endTime":"0","summary":"BOSTON, June  12, 2026  (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with r","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/06/12/3311304/0/en/Rhythm-Pharmaceuticals-to-Announce-Interim-Six-Month-Phase-2-Results-Evaluating-Setmelanotide-in-Patients-with-Prader-Willi-Syndrome.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AVP","PWS","EC","BK4201","VUS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640488519","title":"Lantheus' LNTH-2513 (18F-GP1) PET/CT Awarded SNMMI’s Image of the Year","url":"https://stock-news.laohu8.com/highlight/detail?id=2640488519","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640488519?lang=en_us&edition=fundamental","pubTime":"2026-06-02 20:00","pubTimestamp":1780401600,"startTime":"0","endTime":"0","summary":" 18F-GP1 PET/CT images from a 75-year-old woman show multiple blood clots in the deep veins of the left leg , as well as several clots in the right calf. Venous ultrasound confirms blood clots in left thigh, knee and calf veins. PET/CT also detects clots in both lungs, which are confirmed by contrast-enhanced CT image.  18F-GP1 PET/CT images from a 70-year-old woman show widespread blood clots throughout the body. In addition to clots in the deep veins of both legs and the arteries of both lungs , the scan also detected unexpected clots in several other areas, including blood vessels near the skull/head , spine , heart , and pelvis . Further evaluation revealed that the patient had antiphospholipid syndrome, an autoimmune condition that increases the risk of abnormal blood clot formation.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/06/02/3305065/0/en/Lantheus-LNTH-2513-18F-GP1-PET-CT-Awarded-SNMMI-s-Image-of-the-Year.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BMG7P702.HKD","E","LU1668664300.SGD","BK4161","LU0203347892.USD","D","LU0072461881.USD","LU1023059493.AUD","LU0345780521.USD","A","LU1244550221.USD","IE00BN0W2V16.EUR","IE00BD4GTT62.SGD","BK4198","LU2462157665.USD","BK4208","LU0612318971.USD","LU0345781412.USD","LU2360032135.SGD","BK4585","LU2236285917.USD","IE00BZ18W340.USD","LU1543694498.USD","LU1430597077.USD","LU1791807156.HKD","LU0106831901.USD","IE00BSNM7G36.USD","BU","LU1201861249.SGD","LU0498741114.HKD","SG9999001143.SGD","LU0654597011.USD","LU1162221912.USD","LU2413666699.HKD","LU0128525689.USD","IE00BMG7P819.SGD","BK4207","IE00BD4GTW91.USD","LU0496367417.USD","LU0498741890.SGD","LU0320765646.SGD","BK4559","VUS","LU0345780950.USD","LU0170899867.USD","LU1366192091.USD","LNTH","LU0203345920.USD","CUL3","B"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2639862225","title":"Rhythm Pharmaceuticals Announces Seven Abstracts Accepted for Presentation at ENDO 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2639862225","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2639862225?lang=en_us&edition=fundamental","pubTime":"2026-05-29 20:00","pubTimestamp":1780056000,"startTime":"0","endTime":"0","summary":"BOSTON, May  29, 2026  (GLOBE NEWSWIRE) --  Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with r","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/29/3303535/0/en/Rhythm-Pharmaceuticals-Announces-Seven-Abstracts-Accepted-for-Presentation-at-ENDO-2026.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ENDO","BK4201","BK4183","EC","PWS","VUS","AVP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638698175","title":"Rhythm Pharmaceuticals Announces Publication of New Bardet-Biedl Syndrome Diagnostic Algorithm in the American Journal of Medical Genetics","url":"https://stock-news.laohu8.com/highlight/detail?id=2638698175","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638698175?lang=en_us&edition=fundamental","pubTime":"2026-05-28 20:00","pubTimestamp":1779969600,"startTime":"0","endTime":"0","summary":"BOSTON, May  28, 2026  (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with ra","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/28/3302763/0/en/Rhythm-Pharmaceuticals-Announces-Publication-of-New-Bardet-Biedl-Syndrome-Diagnostic-Algorithm-in-the-American-Journal-of-Medical-Genetics.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4201","BK4117","BK4183","EC","AVP","AFG","ENDO","VUS","BK4107"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638514825","title":"Rhythm Pharmaceuticals Announces Participation in Upcoming Investor Conferences","url":"https://stock-news.laohu8.com/highlight/detail?id=2638514825","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638514825?lang=en_us&edition=fundamental","pubTime":"2026-05-26 20:00","pubTimestamp":1779796800,"startTime":"0","endTime":"0","summary":"BOSTON, May  26, 2026  (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with ra","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/26/3300998/0/en/Rhythm-Pharmaceuticals-Announces-Participation-in-Upcoming-Investor-Conferences.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EC","BK4201","AVP","VUS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634219760","title":"Rhythm Pharmaceuticals Announces New Data Presentations at the 2026 European Congress of Endocrinology","url":"https://stock-news.laohu8.com/highlight/detail?id=2634219760","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634219760?lang=en_us&edition=fundamental","pubTime":"2026-05-12 20:00","pubTimestamp":1778587200,"startTime":"0","endTime":"0","summary":"– Real world data showed clinically meaningful BMI reductions with setmelanotide in 62 adults with 12-month data living with acquired hypothalamic obesity (HO) in France – – Phase 3 analyses demonstra","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/12/3292752/0/en/Rhythm-Pharmaceuticals-Announces-New-Data-Presentations-at-the-2026-European-Congress-of-Endocrinology.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4201","VUS","CP","LU1261432733.SGD","LU1989763690.USD","EC","BK4016","EPV","LU1989763427.SGD","AVP","BK4585","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633013363","title":"Rhythm Pharmaceuticals Announces Participation in Upcoming Bank of America Global Healthcare Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2633013363","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633013363?lang=en_us&edition=fundamental","pubTime":"2026-05-06 20:00","pubTimestamp":1778068800,"startTime":"0","endTime":"0","summary":"BOSTON, May  06, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rar","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/06/3288752/0/en/Rhythm-Pharmaceuticals-Announces-Participation-in-Upcoming-Bank-of-America-Global-Healthcare-Conference.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1894683348.USD","LU0417517546.SGD","LU0208291251.USD","EC","LU0314106906.USD","LU0149725797.USD","LU0234572021.USD","LU0321505439.SGD","BK4207","LU0130102774.USD","LU0477156797.USD","XLV","AVP","LU0306807586.USD","VUS","IE0002270589.USD","IE00BLSP4239.USD","LU1162221912.USD","LU1069347547.HKD","LU0053666078.USD","IE00BLSP4452.SGD","LU0256863811.USD","BAC","LU0640476718.USD","LU0477156953.USD","LU1880398471.USD","LU0310800965.SGD","HCSG","LU0787776722.HKD","LU0211331839.USD","LU1363072403.SGD","LU2265009873.SGD","XBI","LU1804176565.USD","LU1668664300.SGD","LU0234570918.USD","LU1883839398.USD","LU0648001328.SGD","LU2129689431.USD","PGF","LU2129689514.USD","LU0052756011.USD","LU0128525689.USD","LU0128526141.USD","BK4534","LU1496350502.SGD","LU0130103400.USD","LABU","BK4201","IE0034235188.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633140419","title":"Rhythm Pharmaceuticals Reports First Quarter 2026 Financial Results and Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2633140419","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633140419?lang=en_us&edition=fundamental","pubTime":"2026-05-05 19:00","pubTimestamp":1777978800,"startTime":"0","endTime":"0","summary":"-- IMCIVREE (setmelanotide) launched in the U.S. for acquired hypothalamic obesity; more than 150 patient start forms received in the first six weeks following FDA approval on March 19, 2026 -- -- Fir","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/05/3287506/0/en/Rhythm-Pharmaceuticals-Reports-First-Quarter-2026-Financial-Results-and-Business-Update.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VUS","EC","PWS","CHMP","BK4201","BK4087"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632958408","title":"Rhythm Pharmaceuticals Announces New Data Presentations in Acquired Hypothalamic Obesity at Pediatric Endocrine Society","url":"https://stock-news.laohu8.com/highlight/detail?id=2632958408","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632958408?lang=en_us&edition=fundamental","pubTime":"2026-05-04 20:00","pubTimestamp":1777896000,"startTime":"0","endTime":"0","summary":"-- Pediatric patients (n=10) with acquired hypothalamic obesity achieved sustained reductions in BMI and BMI-Z at 2.5 years of setmelanotide therapy ---- Weight category improvements observed in pedia","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/04/3286656/0/en/Rhythm-Pharmaceuticals-Announces-New-Data-Presentations-in-Acquired-Hypothalamic-Obesity-at-Pediatric-Endocrine-Society.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EC","BK4201","AVP","VUS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632861999","title":"Rhythm Pharmaceuticals Announces IMCIVREE® (Setmelanotide) Granted Marketing Authorization by European Commission for the Treatment of Obesity and Control of Hunger in Patients with Acquired Hypothalamic Obesity","url":"https://stock-news.laohu8.com/highlight/detail?id=2632861999","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632861999?lang=en_us&edition=fundamental","pubTime":"2026-05-01 18:55","pubTimestamp":1777632900,"startTime":"0","endTime":"0","summary":"-- First therapy to be FDA-approved and EC-authorized for acquired hypothalamic obesity -- -- European Commission grants authorization in adults and children 4 years of age and above with acquired hyp","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/01/3285813/0/en/Rhythm-Pharmaceuticals-Announces-IMCIVREE-Setmelanotide-Granted-Marketing-Authorization-by-European-Commission-for-the-Treatment-of-Obesity-and-Control-of-Hunger-in-Patients-with-A.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4157","AVP","VUS","BK4201","BMI","EC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626718729","title":"Rhythm Pharmaceuticals to Report First Quarter 2026 Financial Results on Tuesday, May 5, 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2626718729","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626718729?lang=en_us&edition=fundamental","pubTime":"2026-04-09 20:00","pubTimestamp":1775736000,"startTime":"0","endTime":"0","summary":"BOSTON, April  09, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with r","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/04/09/3270878/0/en/Rhythm-Pharmaceuticals-to-Report-First-Quarter-2026-Financial-Results-on-Tuesday-May-5-2026.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VUS","BK4201","AVP","EC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624650779","title":"Rhythm Pharmaceuticals Announces Changes to Board of Directors","url":"https://stock-news.laohu8.com/highlight/detail?id=2624650779","media":"GlobeNewswire","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624650779?lang=en_us&edition=fundamental","pubTime":"2026-04-03 21:00","pubTimestamp":1775221200,"startTime":"0","endTime":"0","summary":"-- Kim Popovits appointed as new Director; Ed Mathers to depart -- BOSTON, April  03, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/04/03/3268007/0/en/Rhythm-Pharmaceuticals-Announces-Changes-to-Board-of-Directors.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EC","BK4201","VUS","AVP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622868600","title":"Rhythm Pharmaceuticals Receives Positive CHMP Opinion for IMCIVREE® (setmelanotide) for the Treatment of Obesity and Control of Hunger in Patients with Acquired Hypothalamic Obesity due to Hypothalamic Injury or Impairment","url":"https://stock-news.laohu8.com/highlight/detail?id=2622868600","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622868600?lang=en_us&edition=fundamental","pubTime":"2026-03-26 21:01","pubTimestamp":1774530060,"startTime":"0","endTime":"0","summary":"-- European Commission decision anticipated in second quarter of 2026 -- BOSTON, March  26, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceu","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/03/26/3263104/0/en/Rhythm-Pharmaceuticals-Receives-Positive-CHMP-Opinion-for-IMCIVREE-setmelanotide-for-the-Treatment-of-Obesity-and-Control-of-Hunger-in-Patients-with-Acquired-Hypothalamic-Obesity-d.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VUS","BK4081","BK4201","EMA","EC","CHMP","AVP","BK4087"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620627296","title":"Rhythm Pharmaceuticals Announces FDA Approval of IMCIVREE® (setmelanotide) for Patients with Acquired Hypothalamic Obesity","url":"https://stock-news.laohu8.com/highlight/detail?id=2620627296","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620627296?lang=en_us&edition=fundamental","pubTime":"2026-03-20 06:30","pubTimestamp":1773959400,"startTime":"0","endTime":"0","summary":"David Meeker Quote   David Meeker Quote   Dr. Shoemaker quote   Dr. Shoemaker quote   IMCIVREE packaging   IMCIVREE packaging with vial   IMCIVREE 3D Render   IMCIVREE 3D Render  -- First and only FDA","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/03/19/3259502/0/en/Rhythm-Pharmaceuticals-Announces-FDA-Approval-of-IMCIVREE-setmelanotide-for-Patients-with-Acquired-Hypothalamic-Obesity.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BK4157","BK4585","AVP","BMI","LABU","EC","BK4201","VUS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616737488","title":"Rhythm Pharmaceuticals Announces Additional Positive Data from Phase 3 TRANSCEND trial of Setmelanotide in Patients with Acquired Hypothalamic Obesity","url":"https://stock-news.laohu8.com/highlight/detail?id=2616737488","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616737488?lang=en_us&edition=fundamental","pubTime":"2026-03-02 01:30","pubTimestamp":1772386200,"startTime":"0","endTime":"0","summary":"-- -18.8% placebo-adjusted difference in BMI reduction achieved in all patients (N=142) at 52 weeks, including 12 Japanese patients and 10 supplemental patients with acquired hypothalamic obesity --  ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/03/01/3246959/0/en/Rhythm-Pharmaceuticals-Announces-Additional-Positive-Data-from-Phase-3-TRANSCEND-trial-of-Setmelanotide-in-Patients-with-Acquired-Hypothalamic-Obesity.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VUS","CHMP","BK4215","MAA","EMA","BK4081","EC","BK4201","BK4588","BK4585","BK4087"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2612645751","title":"Rhythm Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results on Thursday, February 26, 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2612645751","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612645751?lang=en_us&edition=fundamental","pubTime":"2026-02-17 21:00","pubTimestamp":1771333200,"startTime":"0","endTime":"0","summary":"BOSTON, Feb.  17, 2026  (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with r","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/02/17/3239204/0/en/Rhythm-Pharmaceuticals-to-Report-Fourth-Quarter-and-Full-Year-2025-Financial-Results-on-Thursday-February-26-2026.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4201","VUS","EC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2609261308","title":"Rhythm Pharmaceuticals Announces Participation in Upcoming Guggenheim Biotech Summit","url":"https://stock-news.laohu8.com/highlight/detail?id=2609261308","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609261308?lang=en_us&edition=fundamental","pubTime":"2026-02-05 21:00","pubTimestamp":1770296400,"startTime":"0","endTime":"0","summary":"BOSTON, Feb.  05, 2026  (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with r","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/02/05/3232922/0/en/Rhythm-Pharmaceuticals-Announces-Participation-in-Upcoming-Guggenheim-Biotech-Summit.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EC","VUS","BK4588","LABU","SMMF","BK4201","BK4585","BK4211"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":20,"code":"91000000","status":"200"}]}}